Overview of Flexib

Property	Description
Active Ingredient	Rofecoxib
Form	Oral tablet, oral suspension
Pharmacological Class	Selective Cyclooxygenase-2 (COX-2) Inhibitor
Common Use	Reduction of pain and inflammation
Origin	Synthetic compound

What Type of Medicine is Flexib and What Is Its Core Purpose?

Flexib is a medication containing the active ingredient Rofecoxib, and it is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its core purpose is to provide an analgesic and anti-inflammatory effect, a benefit clinically recognized for managing discomfort associated with general muscle pain. Rofecoxib belongs to the specific subgroup of NSAIDs known as Selective Cyclooxygenase-2 (COX-2) Inhibitors. This classification is critical because it highlights the drug's specialized action; its selective mechanism helps target inflammation with precision. This means the drug is designed to primarily inhibit the COX-2 enzyme, which is largely responsible for generating inflammatory signals in the body, providing a differentiated approach compared to traditional, non-selective NSAIDs. By interrupting this chemical cascade, the medication helps reduce the physical discomfort and physiological symptoms associated with inflammation.

Rofecoxib's Origin, Chemical Nature, and Composition

The active compound Rofecoxib is a synthetic compound, meaning it is manufactured entirely through chemical synthesis and is not derived from natural sources. Flexib is typically marketed as a prescription-only (Rx) medication in the form of a manufactured tablet or oral suspension, often positioned for adult patient groups experiencing chronic discomfort. Flexib is manufactured as a single-ingredient product, containing only Rofecoxib as the therapeutic substance, along with pharmaceutical excipients necessary to create a stable and usable form. These excipients are inert compounds that bind the final product together, ensuring consistency and proper delivery of the active substance once administered.

In What Forms is Flexib Available?

Flexib is supplied for oral administration, most commonly in the physical form of a manufactured tablet. In certain contexts, the active ingredient is also prepared as an oral suspension, offering an alternative preparation suitable for the same route of administration. These forms are designed to ensure accurate and standardized systemic delivery of Rofecoxib throughout the body to achieve its therapeutic anti-inflammatory and pain-relieving effects.

Regulatory References

NIH LiverTox Rofecoxib

Therapeutic Uses of Flexib

What Flexib Treats: Main Uses and Benefits

Flexib is applied across therapeutic domains where additional symptomatic support is needed, primarily to help manage pain and inflammation associated with chronic and acute conditions. The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns. It supports the management of chronic, inflammatory joint diseases like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA).

The medication is relevant for easing symptom clusters that may become intense or disruptive, such as joint pain, swelling, and stiffness. It is also commonly used to help manage symptoms associated with acute or disruptive episodes, including acute pain in adults and the symptoms of Primary Dysmenorrhea (menstrual cramps).

“Applied during phases of increased distress or discomfort, Flexib may assist with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

Quick Fact: Relief for Inflammation-driven Joint Pain is commonly considered relevant, helping patients cope more steadily with symptom fluctuations in conditions like arthritis.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Flexib? — Official Regulatory Information

The eligibility profile for Flexib is strictly defined by government regulatory documents, establishing absolute exclusions and conditional restrictions to ensure patient safety.

Absolute Exclusions (Contraindications)

Official labeling mandates that Flexib must not be used in the following populations:

Hypersensitivity: Individuals with a known allergy or hypersensitivity to the active substance (Flexib) or any of its non-active components (excipients).
Severe Organ Impairment: Patients with severe hepatic impairment or severe active liver disease, as use is strictly forbidden.
Pregnancy: Women in the third trimester of pregnancy (or as specified in the official label), due to documented risk.

Conditional or Restricted Use

Use in the following groups is either not recommended or requires specific precautions and monitoring, as safety is not fully established or risks are elevated:

Pediatric Patients: Use is not established or is restricted below a specific age threshold (e.g., under 12 or 18 years of age) because adequate data on safety and effectiveness in this developing population are insufficient.
The Elderly (Geriatric): Use is permitted but requires special consideration and careful monitoring due to potential differences in drug clearance and increased sensitivity to effects.
Comorbidity Limitations: Patients with moderate hepatic or renal impairment must be treated with caution and may require careful dose adjustment, but use is not universally prohibited.

This structure ensures the medicine is administered only to those populations where the regulatory authority has determined the benefit-risk profile is acceptable, based on the officially approved clinical data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flexib (Rofecoxib) interacts with certain other medicinal products, with documented effects ranging from required co-administration restrictions to pharmacokinetic alterations.

Documented Exposure and Metabolic Interactions

Regulatory information specifies that co-administration with Rifampin, a potent inducer of liver enzymes, results in a significant decrease (50%) in Rofecoxib's plasma concentration. Conversely, Rofecoxib acts as a potent inhibitor of the CYP1A2 enzyme, which leads to a profound increase in the exposure (AUC) of CYP1A2 substrates, notably Tizanidine. Administration with antacids containing calcium carbonate or magnesium/aluminum is also documented to decrease Rofecoxib exposure (AUC and Cmax).

Pharmacodynamic and Administration Restrictions

Official documents indicate that co-administration with Warfarin is associated with an increased risk of serious bleeding events due to a documented increase in Prothrombin Time (INR). Flexib is formally contraindicated for use with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Aspirin due to the risk of allergic-type reactions. Its use is also prohibited during the third trimester of pregnancy and in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Population-Specific Notes

In patients with moderate hepatic insufficiency (Child-Pugh score 7–9), the mean plasma concentrations of Rofecoxib are officially documented to be approximately 55% higher than in healthy individuals, indicating altered drug disposition in this population. No mandatory timing separation rules are documented.

Mechanism of Action

Targeting Prostaglandin Synthesis at the Molecular Level

Flexib's core action is mediated by its components acting as non-selective, reversible inhibitors of Cyclooxygenase (COX) enzymes. This mechanistic interaction blocks the COX-dependent conversion of arachidonic acid into chemical messengers called prostaglandins. These lipid mediators play a primary role in amplifying the body's physiological responses; consequently, reducing their systemic and local concentration is the initial molecular step that defines the drug's activity.

Modulating Systemic and Local Responses

The mechanism involves complementary modulation across physiological systems. One component primarily affects peripheral COX activity at the tissue level, while the other primarily modulates COX activity within the central nervous system (CNS), focusing on the hypothalamic thermoregulatory center. This dual action initiates a change in the body's physiology, contributing both to the dampening of exaggerated local inflammatory responses and to the regulation of the body's core thermoregulatory set point.

Dosage and Administration Information

How to Use Flexib (Rofecoxib): Official Administration Guidelines

Flexib, which contains the active ingredient Rofecoxib, is administered exclusively by the oral route using either the tablet or the oral suspension formulation. The medicine is designed for once daily (QD) dosing across all approved adult and pediatric indications. The dosage regimen is specifically tailored to the intended use, distinguishing between chronic maintenance and short-term acute pain management.

Dosing and Schedule Patterns

Indication	Standard Adult Dose	Maximum Recommended Dose	Duration Pattern
Osteoarthritis (OA)	12.5 mg once daily	25 mg once daily	Long-term (Maintenance)
Rheumatoid Arthritis (RA)	25 mg once daily	25 mg once daily	Long-term (Maintenance)
Acute Pain / Primary Dysmenorrhea	50 mg once daily	50 mg once daily	Short-term (Max. 5 days)

Administration Conditions and Adjustments

Flexib tablets can be taken with or without food as the timing of meals does not significantly alter the overall absorption of the drug. If the oral suspension is being used, it must be shaken well prior to administration to ensure an accurate dose.

Population-specific adjustments are officially required for certain groups. For patients with moderate hepatic impairment (liver disease), the maximum chronic dose is strictly limited to 12.5 mg daily. For pediatric patients being treated for Juvenile Rheumatoid Arthritis, the dose is based on body weight for those 2 to 11 years of age, or a fixed 25 mg once daily for those 12 to 17 years of age.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Flexib

Evidence from Clinical Trials for Osteoarthritis

The research exploring Rofecoxib (Flexib) for Osteoarthritis (OA) was built upon short-term and intermediate-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults diagnosed with OA. Studies examined outcomes related to physical discomfort and daily functioning, monitoring validated indices for pain intensity, joint stiffness, and physical activity level. Findings describe patterns observed in the measured pain and functional scores across the study populations. While research explored short-term symptom changes, the characterization of the consistency and durability of the measured outcomes for periods longer than one year is not fully established. Additionally, the generalizability of findings from the most extended comparative trials requires careful consideration.

Evidence from Clinical Trials for Rheumatoid Arthritis

For Rheumatoid Arthritis (RA), Rofecoxib was studied for in short-term placebo-controlled and active comparator-controlled RCTs. Studies explored outcomes capturing phases of heightened symptom activity, such as changes in the disease activity metrics used by the ACR response criteria, along with patient-reported outcomes describing perceived discomfort. Research describes changes measured during the study period for outcomes linked to inflammatory states. A key limitation is that existing studies provide limited insight into the potential long-term effects on the physical progression of joint damage associated with RA.

Evidence from Studies for Acute Pain and Primary Dysmenorrhea

Research into Rofecoxib's use for acute pain is based on rigorous, single-dose, placebo-controlled RCTs and subsequent Meta-analyses. These studies focused on outcomes describing episodic or acute changes, monitoring specific metrics like the time it took for the first reported measurement of symptom change to occur. For Primary Dysmenorrhea, Rofecoxib was evaluated in specialized randomized trials. It is important to note that the follow-up durations for all these acute pain studies were limited to the short-term. The evidence does not address the comparative evidence or long-term systemic effects associated with repeated use over extended periods are not established.

Evidence in Special or Subgroup Populations

Specific populations have been included in research examining Rofecoxib. For example, studies examined Rofecoxib for use in children with Juvenile Rheumatoid Arthritis (JRA). Additionally, certain comparative trials included data on the use of Rofecoxib in older adults and in patients with particular comorbidities. Results apply only to the populations studied in these clinical trial settings. Data for certain groups, such as very young children, remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Flexib (FAQ)

Q: What is Flexib and how does it work?

Flexib is the brand name for etoricoxib, a nonsteroidal anti-inflammatory drug (NSAID) that belongs to a class called selective COX-2 inhibitors. It works by blocking the action of an enzyme in the body called cyclooxygenase-2 (COX-2).

This enzyme is responsible for producing prostaglandins, chemical substances that cause inflammation, pain, and fever. By blocking COX-2, Flexib helps to reduce pain and swelling in the body.

Q: What conditions is Flexib used to treat?

Flexib is used for treating various conditions in adults and adolescents aged 16 years and older. These include:

Osteoarthritis (OA): For relief of pain and symptoms of inflammation.
Rheumatoid arthritis (RA): For relief of pain and symptoms of inflammation.
Ankylosing spondylitis: For the relief of pain and symptoms of inflammation.
Pain and signs of inflammation associated with acute gouty arthritis.
Short-term treatment of moderate pain following dental surgery.

Q: What is the recommended dosage for Flexib?

Dosage must be determined by a healthcare provider based on the condition being treated, your medical history, and how you respond to the medicine. The usual range of doses for common conditions are:

Osteoarthritis: Typically 30 mg or 60 mg once daily.
Rheumatoid arthritis and Ankylosing spondylitis: Typically 60 mg or 90 mg once daily.
Acute gout: 120 mg once daily, for a maximum of 8 days.
Post-dental surgery pain: 90 mg once daily, for a maximum of 3 days.

Do not exceed the dose prescribed by your doctor. The lowest effective dose for the shortest possible duration should be used.

Q: Should I take Flexib with or without food?

You can take Flexib with or without food. However, taking it with food may help reduce the chance of an upset stomach.

If you take it without food, the effect may start sooner. It should be taken once daily.

Q: What are the possible side effects of Flexib?

Like all medicines, Flexib can cause side effects, although not everybody gets them. Common side effects may include:

Stomach pain or discomfort
Heartburn
Nausea
Headache
Dizziness
Tiredness or weakness
Swelling of the legs or feet due to fluid retention (oedema)
High blood pressure

Serious, but less common, side effects can involve the heart, stomach, or kidneys. You should seek immediate medical attention if you experience signs of a serious reaction, such as chest pain, sudden breathlessness, severe stomach pain, or blood in your vomit or stool.

Q: Who should not take Flexib?

Flexib is not suitable for everyone. Do not take Flexib if you:

Are allergic to etoricoxib or any of the other ingredients.
Are allergic to other NSAIDs (such as aspirin or ibuprofen).
Currently have a stomach ulcer or bleeding in your stomach or intestines.
Have severe liver disease or severe kidney disease.
Are pregnant or planning to become pregnant.
Are breast-feeding.
Have had heart failure or have had heart problems such as heart attack or bypass surgery.
Have uncontrolled high blood pressure.
Have had a stroke.
Have established ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.

How should Flexib be stored and disposed of?

Flexib (Rofecoxib) must be stored strictly according to the conditions defined in the official regulatory labeling.

Official Storage and Handling Requirements

The medication must be maintained at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The product must not be refrigerated or frozen, as these temperatures fall outside the mandated stability range.

All prescription medicines, including Flexib, must be kept out of the sight and reach of children to prevent accidental exposure.

Official Disposal Rules

Disposal instructions from health authorities prioritize the use of drug take-back programs. If a take-back program is unavailable, unused or expired Flexib must be disposed of in the household trash after being mixed with an unappealing substance, like dirt, and sealed in a bag. It must not be flushed down the toilet or poured down a sink.

Flexib